Related Experiment Video

Updated: Feb 3, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.6K

miR-874 regulates multiple-drug resistance in gastric cancer by targeting ATG16L1

Haijin Huang1, Jie Tang2, Lei Zhang2

  • 1Department of General Surgery, Hongze District People's Hospital, Huai'an, Jiangsu 223100, P.R. China.

International Journal of Oncology
|October 16, 2018
PubMed

Insights

MicroRNA-874 can overcome multidrug resistance in gastric cancer by inhibiting autophagy through the ATG16L1 gene. This finding offers a potential strategy to improve chemotherapy effectiveness for gastric cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Chemotherapy is a key treatment for gastric cancer (GC), but its efficacy is often limited by multidrug resistance (MDR).
  • MicroRNA (miR)-874 has previously been implicated in tumor growth, apoptosis, and angiogenesis.
  • The specific role and mechanisms of miR-874 in GC drug resistance remain to be fully elucidated.

Purpose of the Study:

  • To investigate the role and underlying mechanisms of miR-874 in multidrug resistance (MDR) in gastric cancer (GC).
  • To determine if miR-874 can sensitize GC cells to chemotherapy.
  • To identify the molecular targets and pathways regulated by miR-874 in the context of drug resistance.

Main Methods:

  • In vitro experiments involving overexpression of miR-874 in GC cells.
  • Reporter gene assays to identify direct targets of miR-874.
  • Western blot analysis to confirm protein expression levels.
  • Assessment of autophagy-related protein 16-like 1 (ATG16L1) expression and its association with autophagy.
  • Evaluation of the effect of ATG16L1 knockdown and autophagy inhibition on GC cell sensitivity to chemotherapy.

Main Results:

  • Overexpression of miR-874 reversed drug resistance in gastric cancer cells in vitro.
  • Autophagy-related 16-like 1 (ATG16L1) was identified as a direct target of miR-874.
  • ATG16L1 expression was positively correlated with autophagy.
  • Reducing ATG16L1 expression and inhibiting autophagy sensitized GC cells to chemotherapy.
  • A regulatory loop involving miR-874, ATG16L1, and autophagy was identified as crucial in GC multidrug resistance.

Conclusions:

  • MiR-874 inhibits autophagy and sensitizes gastric cancer cells to chemotherapy by targeting ATG16L1.
  • The miR-874/ATG16L1/autophagy pathway plays a significant role in mediating multidrug resistance in GC.
  • MiR-874 demonstrates potential as a prognostic factor and a therapeutic target for overcoming chemotherapeutic resistance in GC.

More Related Videos

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.7K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.6K

Related Concept Videos

Regulation of Expression Occurs at Multiple Steps02:24

Regulation of Expression Occurs at Multiple Steps

Gene expression can be regulated at almost every step from gene to protein. Transcription is the step that is most commonly regulated. This involves the binding of proteins to short regulatory sequences on the DNA. This association can either promote or inhibit the transcription of a gene associated with the respective sequence.
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
26.4K
Regulation of Expression Occurs at Multiple Steps02:24

Regulation of Expression Occurs at Multiple Steps

4.0K
Regulation of Expression at Multiple Steps01:23

Regulation of Expression at Multiple Steps

The gene expression in cells is regulated at different stages: (i) transcription, (ii) RNA processing, (iii) RNA localization, and (iv) translation. Transcriptional regulation is mediated by regulatory proteins such as transcription factors, activators, or repressors—these control gene expression by initiating or inhibiting the transcription of genes. Once a precursor or pre-mRNA is produced, it undergoes post-transcriptional modification, including 5' capping, splicing, and the...
1.4K
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
159